Continued growth for Medincell and new prospects with Olanzapine LAI

The Montpellier-based laboratory Medincell is seeing its collaboration with Teva Pharmaceuticals bear fruit. Teva's announcement of its upcoming application for marketing authorization in the United States for Olanzapine LAI demonstrates the growing interest in long-acting injectable treatments. This monthly injection could transform the management of schizophrenia in the United States, particularly for patients currently taking oral olanzapine.

Since its launch in the United States in May 2023, UZEDY®, a subcutaneous risperidone injection, has experienced remarkable growth. Sales reached $136 million in 2025, marking an 82% increase over the previous year. The outlook for 2025 remains optimistic, with sales forecasts between $190 million and $200 million. Medincell benefits from significant royalties and potential commercial milestones.